SOURCE: Protein Polymer Technologies, Inc.

July 16, 2007 07:00 ET

Protein Polymer Technologies Signs Agreement to Provide Biomaterials for Use in Prevention of Post-Surgical Adhesions

SAN DIEGO, CA--(Marketwire - July 16, 2007) - Protein Polymer Technologies, Inc. (OTCBB: PPTI), a biotechnology device company that is a pioneer in protein design and synthesis, announced today that they have entered into an agreement with a multinational biotechnology device company. According to the agreement, PPTI will provide genetically engineered protein polymer biomaterials for use in the prevention of post-surgical adhesions. "This agreement further demonstrates our core competency; developing novel protein polymer biomaterials for challenging medical applications such as the prevention of surgical adhesions," said William N. Plamondon, Chief Executive Officer of PPTI. "Additionally, it furthers the progression of our plan to establish relationships with partners that will ultimately market the products. This relationship adds to the six others we have in product development which includes our license agreements with Spine Wave, Inc. and Genencor International, Inc."

Post-operative adhesions, unintended attachments between distinct tissues and organs in the body, occur after most surgical procedures. Most notable are the complications that arise from adhesions after abdominal and gynecological surgery. Studies have shown that between 55% and 100% of patients developed adhesions within six months of surgery. In severe cases, adhesions can cause pain, obstructions and infertility. More than 300,000 Americans are hospitalized each year at a cost of $1.3 billion to undergo surgery to remove adhesions. PPTI believes its protein polymer materials can improve the outcome of abdominal and gynecological surgery by substantially reducing adhesions.

PPTI is also in discussions with several U.S. and international biotechnology and medical device companies, which are evaluating PPTI's surgical sealant and drug delivery product applications. These products are intended to aid in the closure of surgical incisions and tissue trauma reducing, for example, the incidence of post-operative bleeding and the delivery locally of therapeutic agents. "We have been successful here because of the competencies we've developed in manufacturing products, supporting clinical trials, and engineering application and delivery systems that support the biomaterials platform that we own," said Joe Cappello, Chief Technology Officer of PPTI.

About Protein Polymer Technologies, Inc.

Protein Polymer Technologies, Inc. is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The company is headquartered in San Diego, California. For additional information about the company, please visit

To date, PPTI has been issued twenty-six U.S. Patents on its core technology with corresponding issued and pending patents in key international markets.

This press release contains forward-looking statements that are based on management's views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company's activities include raising adequate capital to continue operations, scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company's 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.

Contact Information

  • Investor/Media Contact:
    Erin Davis
    (858) 558-6064 x 120
    Protein Polymer Technologies, Inc.